Omalizumab biosimilar - Mabtech/Sorrento

Drug Profile

Omalizumab biosimilar - Mabtech/Sorrento

Alternative Names: STI-004

Latest Information Update: 19 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mabtech
  • Developer Mabtech Limited
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic asthma

Most Recent Events

  • 16 May 2016 Efficacy and adverse events data from a phase II/III Allergic asthma trial released by Sorrento Therapeutics
  • 15 Mar 2016 Biomarkers information updated
  • 03 Aug 2015 Monoclonal antibody biosimilar licensed to Sorrento Therapeutics for the treatment of Allergic asthma in European Union, Japan and North America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top